Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

RN Amaria, AM Menzies, EM Burton… - The Lancet …, 2019 - thelancet.com
Advances in the treatment of metastatic melanoma have improved responses and survival.
However, many patients continue to experience resistance or toxicity to treatment …

Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response

CN Spencer, JL McQuade, V Gopalakrishnan… - Science, 2021 - science.org
Gut bacteria modulate the response to immune checkpoint blockade (ICB) treatment in
cancer, but the effect of diet and supplements on this interaction is not well studied. We …

Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials

MS Pelster, RN Amaria - Therapeutic advances in medical …, 2019 - journals.sagepub.com
The development of BRAF and MEK inhibitors (BRAFis and MEKis) and immune checkpoint
inhibitors have changed the management of advanced stage melanoma and improved the …

[HTML][HTML] Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients

MT Tetzlaff, KC Nelson, A Diab, GA Staerkel… - … for immunotherapy of …, 2018 - Springer
Background Immune checkpoint therapy has dramatically changed the landscape of cancer
therapy, providing an efficacious and durable therapeutic option for patients with advanced …

B cells and tertiary lymphoid structures promote immunotherapy response

BA Helmink, SM Reddy, J Gao, S Zhang, R Basar… - Nature, 2020 - nature.com
Abstract Treatment with immune checkpoint blockade (ICB) has revolutionized cancer
therapy. Until now, predictive biomarkers,,,,,,,,–and strategies to augment clinical response …

Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade

PL Chen, W Roh, A Reuben, ZA Cooper, CN Spencer… - Cancer discovery, 2016 - AACR
Immune checkpoint blockade represents a major breakthrough in cancer therapy; however,
responses are not universal. Genomic and immune features in pretreatment tumor biopsies …

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

MC Andrews, CPM Duong, V Gopalakrishnan… - Nature medicine, 2021 - nature.com
Abstract Treatment with combined immune checkpoint blockade (CICB) targeting CTLA-4
and PD-1 is associated with clinical benefit across tumor types, but also a high rate of …

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

RN Amaria, SM Reddy, HA Tawbi, MA Davies… - Nature medicine, 2018 - nature.com
Preclinical studies suggest that treatment with neoadjuvant immune checkpoint blockade is
associated with enhanced survival and antigen-specific T cell responses compared with …

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance

W Roh, PL Chen, A Reuben, CN Spencer… - Science translational …, 2017 - science.org
Immune checkpoint blockade produces clinical benefit in many patients. However, better
biomarkers of response are still needed, and mechanisms of resistance remain incompletely …

[HTML][HTML] Neoadjuvant relatlimab and nivolumab in resectable melanoma

RN Amaria, M Postow, EM Burton, MT Tetzlaff, MI Ross… - Nature, 2022 - nature.com
Relatlimab and nivolumab combination immunotherapy improves progression-free survival
over nivolumab monotherapy in patients with unresectable advanced melanoma. We …